As scientists continue to investigate the roots of autism, a generic cancer drug might hold the key. Leucovorin is prescribed ...

A generic cancer drug is reportedly responsible for children with autism showing "drastic improvement," the New York Post ...

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the ...

In a 2020 study, he found that two-thirds of 44 children with both autism and folate receptor alpha autoantibodies showed improvements in language after taking the drug. Another study he published ...

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

AbbVie has reported analysis from a Phase III trial that assessed Elahere against chemotherapy for platinum-resistant ovarian ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Genmab (GMAB) announced updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan, an investigational folate ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost entirely from the US market and before the contribution from Europe was ready ...